When does a biotech consider a captive insurance company versus a group captive?

A captive insurance company is a licensed insurance entity owned by its insureds, used to retain risk that would otherwise be transferred to commercial carriers. The economic case is straightforward: when an operator pays meaningful premium for losses that don't materialize, the loss ratio benefit accrues to the carrier; in a captive, the underwriting profit accrues to the captive's owners.

The threshold for single-parent captive economics is generally $5M+ annual premium across the program, where the captive's operational overhead (fronting fees, captive management, actuarial, accounting, audit, premium tax) is justified by the underwriting-result capture. Group captives lower the threshold to $250K-$1M by aggregating multiple insureds; segregated portfolio companies (SPCs) and protected cell companies (PCCs) further reduce overhead per insured.

Late-stage biotech with substantial program premium ($5M+) and multiple historical years of favorable loss experience, where retention of the underwriting profit becomes material. Cell and gene therapy operators with high clinical trial liability premium and predictable, well-modeled loss profiles. Medical device operators with mature products liability programs and substantial premium spend.

Biotechs that have outgrown what the commercial market will price competitively — when the program has grown beyond a single carrier's appetite and quote competition has thinned.

Group captives aggregate multiple unrelated insureds (typically 10-50 companies) in similar industries to achieve underwriting-result-sharing without each member needing $5M+ premium. A biotech-focused group captive (or a broader life-sciences group captive) typically requires $250K-$1M annual premium from each member and accepts only members with favorable loss experience.

The economic benefit is shared but real: members share in the underwriting profit when the group runs better than expected, and share in the deficit when it doesn't. Group captives typically operate on a 5-10 year horizon to smooth loss experience.

Single-parent captives require fronting carrier arrangements (a licensed carrier issues the policy and reinsures back to the captive), captive management (typically a third-party captive manager based in a captive domicile like Vermont, Bermuda, Cayman), actuarial reserving, premium tax in the operating jurisdictions, and ongoing regulatory filings in the captive domicile.

The IRS scrutinizes small captives (831(b) elections) for legitimate insurance purpose; the tax case law on "risk distribution" and "risk shifting" is detailed. Biotechs considering captive structures should work with tax counsel and captive consultants who specialize in insurance taxation.

Pre-clinical and clinical-stage biotechs with limited operating history and limited loss data do not have the actuarial basis for captive underwriting. Programs under $1M total premium do not justify single-parent captive operational overhead.

Programs that require occurrence-form coverage on long-tail life sciences exposures (implantable devices, pharmaceuticals) face commercial-market constraints that are difficult to replicate inside a captive without substantial commercial reinsurance backstop.